Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-12-28 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
CALQUENCE JAPAN APPROVAL FOR TREATMENT-NAIVE CLL
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the announcement of the approval of Calquence in Japan for treatment-naïve chronic lymphocytic leukemia (CLL), including clinical trial results and regulatory approval details. There are no financial statements or comprehensive financial performance data presented. The document is an announcement of a regulatory approval event and clinical trial results rather than a financial report or earnings release. Form 6-K filings typically serve as regulatory filings for foreign issuers to disclose material information to the SEC. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (over 14,000 characters) and detailed content support this classification rather than a brief announcement or report publication announcement.
2022-12-28 English
IMFINZI, IMJUDO APPROVED IN JAPAN FOR 3 CANCERS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It contains detailed information about the approval of drugs Imfinzi and Imjudo in Japan for treatment of various cancers, including clinical trial results and regulatory approvals. The document is not an annual report, earnings release, or financial statement. It is a regulatory filing providing material corporate news and updates about product approvals and clinical trial outcomes. The document length is about 15,000 characters, and it is a standalone report submitted to the SEC as a Form 6-K, which is typically classified under Regulatory Filings (RNS) in this taxonomy. There is no indication that this is a presentation, call transcript, or other specific report type. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-12-28 English
Calquence Japan approval for treatment-naïve CLL
Regulatory Filings Classification · 100% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement by the header 'RNS Number : 9726K' and the concluding boilerplate text mentioning RNS and the London Stock Exchange. The content is a press release announcing a regulatory approval (Calquence approved in Japan) and provides key clinical data highlights. Since it is a general regulatory announcement that doesn't fit neatly into specific financial report categories (like 10-K, ER, or IR), and it is distributed via the RNS system, the most appropriate classification is Regulatory Filings (RNS). The document length (14,553 chars) is substantial, indicating it is the full announcement, not just a short notice of publication (which would suggest RPA).
2022-12-28 English
Imfinzi, Imjudo approved in Japan for 3 cancers
Regulatory Filings Classification · 100% confidence The document is a press release from AstraZeneca dated December 28, 2022, announcing regulatory approvals for its drugs (Imfinzi and Imjudo) in Japan for various cancer treatments (HCC, NSCLC, BTC). It details the basis for these approvals, citing specific Phase III trials (HIMALAYA, POSEIDON, TOPAZ-1) and providing extensive clinical data summaries. This content structure—announcing regulatory news, citing trial data, and providing context on the disease/drug—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of a significant corporate event (drug approval) rather than a general regulatory notice or a full financial report (like 10-K or IR), and it is not a transcript or a presentation, the most fitting category is Earnings Release (ER) as these announcements often accompany or substitute for quarterly financial updates when major news breaks, or RNS as a general regulatory announcement. Given the nature of the announcement (major regulatory approval news), RNS (Regulatory Filings) is the most appropriate general category for non-standard financial reports, although ER is also plausible if this was released around a reporting period. However, RNS is the best fit for a standalone, specific regulatory/corporate action announcement that isn't a core financial statement or call transcript. The document length (23,430 chars) is substantial, ruling out RPA/RNS based on the 'MENU VS MEAL' rule for short announcements.
2022-12-28 English
IMFINZI APPROVED IN EU FOR BILIARY TRACT CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The content focuses on the announcement of the approval of Imfinzi in the EU for biliary tract cancer, including clinical trial results and company statements. There are no financial statements or detailed financial performance data presented. The document is an announcement of a regulatory and product approval event rather than a financial report or earnings release. It is not a full annual or interim report, nor a call transcript or management discussion. Given the nature of the filing (Form 6-K) and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (over 13,000 characters) and detailed content support that it is a substantive regulatory announcement rather than a brief report publication announcement or certification. Therefore, the classification is RNS with high confidence.
2022-12-21 English
LYNPARZA APPROVED IN EU FOR PROSTATE CANCER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It provides detailed information about the approval of Lynparza in the EU for prostate cancer, including clinical trial results, regulatory milestones, and financial considerations. Form 6-K filings are typically used by foreign private issuers to report material information that is not required to be reported on Form 20-F or 40-F. This document is not an annual report, earnings release, or any other specific financial report but rather a regulatory announcement of material information. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains detailed information, not just a brief announcement or certification, supporting this classification with high confidence.
2022-12-21 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.